Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients

B. Keck, S. Wach, H. Taubert, S. Zeiler, O. J. Ott, F. Kunath, A. Hartmann, S. Bertz, C. Weiss, P. Hönscheid, S. Schellenburg, C. Rödel, G. B. Baretton, R. Sauer, R. Fietkau, B. Wullich, F. S. Krause, Kaustubh Datta, M. H. Muders

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The standard treatment for invasive bladder cancer is radical cystectomy. In selected patients, bladder-sparing therapy can be performed by transurethral resection (TURBT) and radio-chemotherapy (RCT) or radiotherapy (RT). Our published in vitro data suggest that the Neuropilin-2 (NRP2)/VEGF-C axis plays a role in therapy resistance. Therefore, we studied the prognostic impact of NRP2 and VEGF-C in 247 bladder cancer patients (cN0M0) treated with TURBT and RCT (n = 198) or RT (n = 49) and a follow-up time up to 15 years. A tissue microarray was analyzed by immunohistochemistry. NRP2 expression emerged as a prognostic factor in overall survival (OS; HR: 3.42; 95% CI: 1.48 - 7.86; p = 0.004) and was associated with a 3.85-fold increased risk of an early cancer specific death (95% CI: 0.91 - 16.24; p = 0.066) in multivariate analyses. Cancer specific survival (CSS) dropped from 166 months to 85 months when NRP2 was highly expressed (p = 0.037). Patients with high VEGF-C expression have a 2.29-fold increased risk of shorter CSS (95% CI: 1.03-5.35; p = 0.043) in univariate analysis. CSS dropped from 170 months to 88 months in the case of high VEGF-C expression (p = 0.041). Additionally, NRP2 and VEGF-C coexpression is a prognostic marker for OS in multivariate models (HR: 7.54; 95% CI: 1.57-36.23; p = 0.012). Stratification for muscle invasiveness (T1 vs. T2-T4) confirmed the prognostic role of NRP2 and NRP2/VEGF-C co-expression in patients with T2-T4 but also with high risk T1 disease. In conclusion, immunohistochemistry for NRP2 and VEGF-C has been determined to predict therapy outcome in bladder cancer patients prior to TURBT and RCT. What's new? Neuropilin-2 (NRP2) and VEGF-C may play an important role in resistance to treatment. They can induce anti-apoptotic and autophagic signaling pathways, which protects cancer cells from chemotherapeutic stress in vitro. Therefore, these proteins might be useful as biomarkers for predicting a patient's response to therapy. In this study of bladder cancer patients, the authors demonstrate that NRP2 and VEGF-C expression are indeed prognostic markers. This may allow more patients to be treated with bladder-sparing surgery rather than radical cystectomy, and may also be applicable to other types of cancer.

Original languageEnglish (US)
Pages (from-to)443-451
Number of pages9
JournalInternational Journal of Cancer
Volume136
Issue number2
DOIs
StatePublished - Jan 15 2015

Fingerprint

Neuropilin-2
Vascular Endothelial Growth Factor C
Chemoradiotherapy
Urinary Bladder Neoplasms
Ligands
Radio
Therapeutics
Neoplasms
Survival
Cystectomy
Drug Therapy
Urinary Bladder
Radiotherapy
Immunohistochemistry

Keywords

  • Neuropilin-2
  • TURBT
  • VEGF-C
  • bladder cancer
  • radiochemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. / Keck, B.; Wach, S.; Taubert, H.; Zeiler, S.; Ott, O. J.; Kunath, F.; Hartmann, A.; Bertz, S.; Weiss, C.; Hönscheid, P.; Schellenburg, S.; Rödel, C.; Baretton, G. B.; Sauer, R.; Fietkau, R.; Wullich, B.; Krause, F. S.; Datta, Kaustubh; Muders, M. H.

In: International Journal of Cancer, Vol. 136, No. 2, 15.01.2015, p. 443-451.

Research output: Contribution to journalArticle

Keck, B, Wach, S, Taubert, H, Zeiler, S, Ott, OJ, Kunath, F, Hartmann, A, Bertz, S, Weiss, C, Hönscheid, P, Schellenburg, S, Rödel, C, Baretton, GB, Sauer, R, Fietkau, R, Wullich, B, Krause, FS, Datta, K & Muders, MH 2015, 'Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients', International Journal of Cancer, vol. 136, no. 2, pp. 443-451. https://doi.org/10.1002/ijc.28987
Keck, B. ; Wach, S. ; Taubert, H. ; Zeiler, S. ; Ott, O. J. ; Kunath, F. ; Hartmann, A. ; Bertz, S. ; Weiss, C. ; Hönscheid, P. ; Schellenburg, S. ; Rödel, C. ; Baretton, G. B. ; Sauer, R. ; Fietkau, R. ; Wullich, B. ; Krause, F. S. ; Datta, Kaustubh ; Muders, M. H. / Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. In: International Journal of Cancer. 2015 ; Vol. 136, No. 2. pp. 443-451.
@article{c80be35e8edb488b86c8c67e8528a966,
title = "Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients",
abstract = "The standard treatment for invasive bladder cancer is radical cystectomy. In selected patients, bladder-sparing therapy can be performed by transurethral resection (TURBT) and radio-chemotherapy (RCT) or radiotherapy (RT). Our published in vitro data suggest that the Neuropilin-2 (NRP2)/VEGF-C axis plays a role in therapy resistance. Therefore, we studied the prognostic impact of NRP2 and VEGF-C in 247 bladder cancer patients (cN0M0) treated with TURBT and RCT (n = 198) or RT (n = 49) and a follow-up time up to 15 years. A tissue microarray was analyzed by immunohistochemistry. NRP2 expression emerged as a prognostic factor in overall survival (OS; HR: 3.42; 95{\%} CI: 1.48 - 7.86; p = 0.004) and was associated with a 3.85-fold increased risk of an early cancer specific death (95{\%} CI: 0.91 - 16.24; p = 0.066) in multivariate analyses. Cancer specific survival (CSS) dropped from 166 months to 85 months when NRP2 was highly expressed (p = 0.037). Patients with high VEGF-C expression have a 2.29-fold increased risk of shorter CSS (95{\%} CI: 1.03-5.35; p = 0.043) in univariate analysis. CSS dropped from 170 months to 88 months in the case of high VEGF-C expression (p = 0.041). Additionally, NRP2 and VEGF-C coexpression is a prognostic marker for OS in multivariate models (HR: 7.54; 95{\%} CI: 1.57-36.23; p = 0.012). Stratification for muscle invasiveness (T1 vs. T2-T4) confirmed the prognostic role of NRP2 and NRP2/VEGF-C co-expression in patients with T2-T4 but also with high risk T1 disease. In conclusion, immunohistochemistry for NRP2 and VEGF-C has been determined to predict therapy outcome in bladder cancer patients prior to TURBT and RCT. What's new? Neuropilin-2 (NRP2) and VEGF-C may play an important role in resistance to treatment. They can induce anti-apoptotic and autophagic signaling pathways, which protects cancer cells from chemotherapeutic stress in vitro. Therefore, these proteins might be useful as biomarkers for predicting a patient's response to therapy. In this study of bladder cancer patients, the authors demonstrate that NRP2 and VEGF-C expression are indeed prognostic markers. This may allow more patients to be treated with bladder-sparing surgery rather than radical cystectomy, and may also be applicable to other types of cancer.",
keywords = "Neuropilin-2, TURBT, VEGF-C, bladder cancer, radiochemotherapy",
author = "B. Keck and S. Wach and H. Taubert and S. Zeiler and Ott, {O. J.} and F. Kunath and A. Hartmann and S. Bertz and C. Weiss and P. H{\"o}nscheid and S. Schellenburg and C. R{\"o}del and Baretton, {G. B.} and R. Sauer and R. Fietkau and B. Wullich and Krause, {F. S.} and Kaustubh Datta and Muders, {M. H.}",
year = "2015",
month = "1",
day = "15",
doi = "10.1002/ijc.28987",
language = "English (US)",
volume = "136",
pages = "443--451",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients

AU - Keck, B.

AU - Wach, S.

AU - Taubert, H.

AU - Zeiler, S.

AU - Ott, O. J.

AU - Kunath, F.

AU - Hartmann, A.

AU - Bertz, S.

AU - Weiss, C.

AU - Hönscheid, P.

AU - Schellenburg, S.

AU - Rödel, C.

AU - Baretton, G. B.

AU - Sauer, R.

AU - Fietkau, R.

AU - Wullich, B.

AU - Krause, F. S.

AU - Datta, Kaustubh

AU - Muders, M. H.

PY - 2015/1/15

Y1 - 2015/1/15

N2 - The standard treatment for invasive bladder cancer is radical cystectomy. In selected patients, bladder-sparing therapy can be performed by transurethral resection (TURBT) and radio-chemotherapy (RCT) or radiotherapy (RT). Our published in vitro data suggest that the Neuropilin-2 (NRP2)/VEGF-C axis plays a role in therapy resistance. Therefore, we studied the prognostic impact of NRP2 and VEGF-C in 247 bladder cancer patients (cN0M0) treated with TURBT and RCT (n = 198) or RT (n = 49) and a follow-up time up to 15 years. A tissue microarray was analyzed by immunohistochemistry. NRP2 expression emerged as a prognostic factor in overall survival (OS; HR: 3.42; 95% CI: 1.48 - 7.86; p = 0.004) and was associated with a 3.85-fold increased risk of an early cancer specific death (95% CI: 0.91 - 16.24; p = 0.066) in multivariate analyses. Cancer specific survival (CSS) dropped from 166 months to 85 months when NRP2 was highly expressed (p = 0.037). Patients with high VEGF-C expression have a 2.29-fold increased risk of shorter CSS (95% CI: 1.03-5.35; p = 0.043) in univariate analysis. CSS dropped from 170 months to 88 months in the case of high VEGF-C expression (p = 0.041). Additionally, NRP2 and VEGF-C coexpression is a prognostic marker for OS in multivariate models (HR: 7.54; 95% CI: 1.57-36.23; p = 0.012). Stratification for muscle invasiveness (T1 vs. T2-T4) confirmed the prognostic role of NRP2 and NRP2/VEGF-C co-expression in patients with T2-T4 but also with high risk T1 disease. In conclusion, immunohistochemistry for NRP2 and VEGF-C has been determined to predict therapy outcome in bladder cancer patients prior to TURBT and RCT. What's new? Neuropilin-2 (NRP2) and VEGF-C may play an important role in resistance to treatment. They can induce anti-apoptotic and autophagic signaling pathways, which protects cancer cells from chemotherapeutic stress in vitro. Therefore, these proteins might be useful as biomarkers for predicting a patient's response to therapy. In this study of bladder cancer patients, the authors demonstrate that NRP2 and VEGF-C expression are indeed prognostic markers. This may allow more patients to be treated with bladder-sparing surgery rather than radical cystectomy, and may also be applicable to other types of cancer.

AB - The standard treatment for invasive bladder cancer is radical cystectomy. In selected patients, bladder-sparing therapy can be performed by transurethral resection (TURBT) and radio-chemotherapy (RCT) or radiotherapy (RT). Our published in vitro data suggest that the Neuropilin-2 (NRP2)/VEGF-C axis plays a role in therapy resistance. Therefore, we studied the prognostic impact of NRP2 and VEGF-C in 247 bladder cancer patients (cN0M0) treated with TURBT and RCT (n = 198) or RT (n = 49) and a follow-up time up to 15 years. A tissue microarray was analyzed by immunohistochemistry. NRP2 expression emerged as a prognostic factor in overall survival (OS; HR: 3.42; 95% CI: 1.48 - 7.86; p = 0.004) and was associated with a 3.85-fold increased risk of an early cancer specific death (95% CI: 0.91 - 16.24; p = 0.066) in multivariate analyses. Cancer specific survival (CSS) dropped from 166 months to 85 months when NRP2 was highly expressed (p = 0.037). Patients with high VEGF-C expression have a 2.29-fold increased risk of shorter CSS (95% CI: 1.03-5.35; p = 0.043) in univariate analysis. CSS dropped from 170 months to 88 months in the case of high VEGF-C expression (p = 0.041). Additionally, NRP2 and VEGF-C coexpression is a prognostic marker for OS in multivariate models (HR: 7.54; 95% CI: 1.57-36.23; p = 0.012). Stratification for muscle invasiveness (T1 vs. T2-T4) confirmed the prognostic role of NRP2 and NRP2/VEGF-C co-expression in patients with T2-T4 but also with high risk T1 disease. In conclusion, immunohistochemistry for NRP2 and VEGF-C has been determined to predict therapy outcome in bladder cancer patients prior to TURBT and RCT. What's new? Neuropilin-2 (NRP2) and VEGF-C may play an important role in resistance to treatment. They can induce anti-apoptotic and autophagic signaling pathways, which protects cancer cells from chemotherapeutic stress in vitro. Therefore, these proteins might be useful as biomarkers for predicting a patient's response to therapy. In this study of bladder cancer patients, the authors demonstrate that NRP2 and VEGF-C expression are indeed prognostic markers. This may allow more patients to be treated with bladder-sparing surgery rather than radical cystectomy, and may also be applicable to other types of cancer.

KW - Neuropilin-2

KW - TURBT

KW - VEGF-C

KW - bladder cancer

KW - radiochemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84922337206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922337206&partnerID=8YFLogxK

U2 - 10.1002/ijc.28987

DO - 10.1002/ijc.28987

M3 - Article

C2 - 24862180

AN - SCOPUS:84922337206

VL - 136

SP - 443

EP - 451

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -